Last reviewed · How we verify
Ceftolozane-tazobactam IV
Ceftolozane-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.
Ceftolozane-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation. Used for Complicated urinary tract infections (cUTI) including pyelonephritis, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), Complicated intra-abdominal infections (cIAI).
At a glance
| Generic name | Ceftolozane-tazobactam IV |
|---|---|
| Also known as | Zerbaxa |
| Sponsor | Hamad Medical Corporation |
| Drug class | Fifth-generation cephalosporin with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftolozane is a fifth-generation cephalosporin that binds to penicillin-binding proteins and disrupts bacterial cell wall formation. Tazobactam is a beta-lactamase inhibitor that protects ceftolozane from degradation by bacterial beta-lactamases, extending its spectrum of activity against resistant gram-negative organisms including Pseudomonas aeruginosa and Enterobacteriaceae.
Approved indications
- Complicated urinary tract infections (cUTI) including pyelonephritis
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Complicated intra-abdominal infections (cIAI)
Common side effects
- Diarrhea
- Nausea
- Headache
- Hypersensitivity reactions
- Clostridioides difficile infection
Key clinical trials
- Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036) (PHASE1)
- Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients (NA)
- Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis (PHASE4)
- CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients (PHASE4)
- MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) (PHASE2)
- MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) (PHASE2)
- Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) (PHASE3)
- Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftolozane-tazobactam IV CI brief — competitive landscape report
- Ceftolozane-tazobactam IV updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI